DroneShield Beset by Regulatory Probe and Jefferies Downgrade as Short Sellers Tighten Grip

DroneShield shares fall 25% in 30 days amid Jefferies downgrade to €1.24 target and ASIC investigation. Record 12.19% short interest as bearish sentiment deepens.

DroneShield’s stock has been battered from two directions this month, leaving it trading at €1.30 after a 7.18% drop on Friday and a near-25% decline over the past 30 days. The counter-drone specialist is wrestling with both a freshly slashed price target from Jefferies and an unresolved investigation by Australia’s securities regulator, giving short sellers ample ammunition to build record bearish positions.

Jefferies maintained its "Underperform" rating while cutting its price target sharply from A$2.80 to A$2.05 — equivalent to roughly €1.24. The bank trimmed its revenue forecasts for the 2026 through 2028 fiscal years by about 9% and lowered earnings-per-share estimates by between 5% and 16%. Even a new large contract, the analysts argued, would provide only limited near-term relief; they expect a string of smaller orders rather than a single blockbuster deal. The stock’s valuation premium over sector peers remains a key sticking point.

The Jefferies downgrade arrives as the Australian Securities and Investments Commission continues its examination of DroneShield’s market disclosures and share trading between 1 and 20 November 2025, with a specific focus on equity transactions from 6 to 12 November. The probe follows last year’s sale of A$67 million worth of shares by former executives and a misreported US contract — events that eroded investor confidence and triggered a severe sell-off. DroneShield has pledged to cooperate but cannot yet predict whether the review will lead to penalties.

Record short interest reflects the deepening scepticism. Some 12.19% of DroneShield’s shares are now held short, the highest level ever for the stock. That concentration magnifies any negative news, while positive developments require greater force to spark a short squeeze. Still, the bearish thesis has a potential weak point: the company’s revenue mix is shifting. In 2025, hardware sales generated 91% of revenue and subscriptions only 5%, but recurring revenue already accounts for 13% of committed sales for fiscal 2026. A confirmed major order could force short sellers to cover in a hurry.

Technical indicators suggest the sell-off has become extreme. The 14-day relative strength index stands at 32.9, flirting with the classic oversold threshold. The share price sits 23.29% below its 50-day moving average of €1.69 and 32.90% below its 200-day average of €1.94. Over the past 52 weeks, DroneShield has swung from a high of €3.65 in October 2025 to a low of €0.82 in late November — a range that underscores the stock’s volatility.

Adding to the uncertainty, DroneShield is no longer required to publish quarterly cash-flow reports, having stopped the practice in May. The next mandatory update will not arrive until the half-year results for the six months ending 30 June 2026, scheduled for 26 August 2026. In the meantime, investors must rely on older data: first-quarter 2026 revenue of A$74.1 million (roughly €45 million), a committed backlog of A$154.8 million, and recent wins including a US order worth at least A$10 million and a US Department of Defence contract valued at US$24.9 million. Without fresh cash-flow figures, the market is scrutinising every contract announcement for clues on margins and delivery quality.

Competitive pressure is also building at home. Rival Electro Optic Systems secured a A$5.7 million government contract on 8 July for its Slinger R400 system, narrowing DroneShield’s lead in the domestic market. Electro Optic Systems remains smaller with a market capitalisation of roughly A$1.78 billion, but the win highlights how DroneShield’s hardware-heavy business model — still reliant on one-off sales rather than recurring subscriptions — leaves it exposed to challengers.

Investors are now in a waiting game. A major new order could act as a circuit breaker, triggering a short squeeze and a rapid recovery. Without one, the confluence of regulatory overhang, analyst downgrades and record short interest is likely to keep the stock pinned near oversold territory until the half-year report sheds more light on the company’s financial health.